U.S. markets open in 5 hours 44 minutes
  • S&P Futures

    3,837.50
    -5.00 (-0.13%)
     
  • Dow Futures

    30,760.00
    -82.00 (-0.27%)
     
  • Nasdaq Futures

    13,544.50
    +59.00 (+0.44%)
     
  • Russell 2000 Futures

    2,135.10
    -10.70 (-0.50%)
     
  • Crude Oil

    53.05
    +0.44 (+0.84%)
     
  • Gold

    1,845.20
    -5.70 (-0.31%)
     
  • Silver

    25.38
    -0.16 (-0.64%)
     
  • EUR/USD

    1.2151
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    23.95
    +0.76 (+3.28%)
     
  • GBP/USD

    1.3731
    -0.0001 (-0.01%)
     
  • USD/JPY

    103.7200
    +0.0930 (+0.09%)
     
  • BTC-USD

    31,415.01
    +10.25 (+0.03%)
     
  • CMC Crypto 200

    630.65
    -9.27 (-1.45%)
     
  • FTSE 100

    6,644.21
    -9.80 (-0.15%)
     
  • Nikkei 225

    28,635.21
    +89.03 (+0.31%)
     

LAWSUITS FILED AGAINST GOCO, MESO and ZSAN - Jakubowitz Law Pursues Shareholders Claims

·4 min read

NEW YORK, NY / ACCESSWIRE / November 11, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

GoHealth, Inc. (NASDAQ:GOCO)

CONTACT JAKUBOWITZ ABOUT GOCO:
https://claimyourloss.com/securities/gohealth-inc-loss-submission-form/?id=10862&from=1

The GoHealth lawsuit is on behalf of all purchasers of GoHealth Class A common stock pursuant and/or traceable to the registration statement issued in connection with GoHealth's July 2020 initial public offering.

Lead Plaintiff Deadline: November 20, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (ii) GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base; (iii) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company's concentrated carrier business model, and GoHealth's efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (iv) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (v) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the initial public offering.

Mesoblast Limited (NASDAQ:MESO)

CONTACT JAKUBOWITZ ABOUT MESO:
https://claimyourloss.com/securities/mesoblast-limited-loss-submission-form/?id=10862&from=1

Class Period : April 16, 2019 - October 1, 2020

Lead Plaintiff Deadline: December 7, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Zosano Pharma Corporation (NASDAQ:ZSAN)

CONTACT JAKUBOWITZ ABOUT ZSAN:
https://claimyourloss.com/securities/zosano-pharma-corporation-loss-submission-form/?id=10862&from=1

Class Period : February 13, 2017 - September 30, 2020

Lead Plaintiff Deadline: December 28, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/616097/LAWSUITS-FILED-AGAINST-GOCO-MESO-and-ZSAN--Jakubowitz-Law-Pursues-Shareholders-Claims